Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, raised $65 million by offering 9.3 million shares at $7, as expected. Prior to postponing its IPO in November 2013, the company had been looking to raise $75 million at a price range of $12 to $14. Trevena plans to list on the NASDAQ under the symbol TRVN. Trevena initially filed confidentially on 9/6/2013. Barclays and Jefferies & Co. acted as joint bookrunners on the deal.
UPDATE: Trevena changed its pricing terms Friday morning. It had previously announced that it was offering 8.5 million shares.